Logo

American Heart Association

  2
  0


Final ID: MDP1334

Outcomes for heart failure patients with reduced ejection fraction attending emergency department and discharged within 24 hours versus those admitted patients in heart failure unit.

Abstract Body (Do not enter title and authors here): Introduction: Heart failure (HF) is a clinical syndrome with increasing prevalence. Currently, there are extensive evidence-based therapies targeted at managing patients with heart failure and reduced ejection fraction (HFrEF) to improve outcomes. The National Heart Failure Audit shows the quality of inpatient care (specialist review, discharge medication etc) is related to outcome. This study aimed to evaluate the current practice at a London tertiary centre hospital in managing patients with heart failure and compared outcomes in patients who had a short course of admission (less than 1 day) with those who had a more prolonged course of admission.

Method: Retrospective data was collected from a London tertiary centre hospital database for consecutive patients from Sep/2022 till Sep/2023. Statistical analysis was performed using Chi-Square test. The eligibility criteria included a new or previous diagnosis of HF with left ventricular ejection fraction (LVEF) < 40%. Patients were divided into two groups: Group A included 40 eligible patients who were admitted and discharged from the emergency department (ED) within 24 hours. Group B included 37 eligible patients who were admitted and discharged from the dedicated heart failure unit after 10-15 days of hospital admission.

Results: In Group A, prescribing guideline-directed medical therapy (GDMT) was lower compared to Group B; Renin-Angiotensin-Aldosterone Inhibitors (47.50% vs. 94.59%), beta blockers (55% vs. 91.89%), mineralocorticoid receptor antagonists (12.50 %vs. 94.59%), and sodium-glucose co-transporter 2 inhibitors (15% vs. 89.19%). More patients in Group B received all four pillars of GDMT (86.49%) compared to Group A (5%). At 6-month follow-up,18.75% were on 4 GDMT in Group A versus 92% in group Group B. Re-admission within 6 months was higher in Group A (30%) compared to Group B (16.22%); however, the difference was not statistically significant (P value: 0.153). Higher mortality rates were observed in Group A (mortality rate: 20%) compared to Group B (mortality rate: 2.70%), with statistical significance (P value: 0.018).

Conclusion: This study showed that HFrEF patients admitted to a specialist heart failure unit achieve higher rates of GDMT and have significantly improved outcomes compared to those who had a shorter inpatient stay and discharged from the emergency department. These findings underscore the high risks associated with rapid discharge from hospital on incomplete medical therapy.
  • Alalawi, Mohamed  ( St Georges Hospital , London , United Kingdom )
  • Jouhra, Fadi  ( St Georges Hospital , London , United Kingdom )
  • Macken, Elizabeth  ( , London , United Kingdom )
  • Begum, Taheba  ( Kingston University , Kingston , United Kingdom )
  • Eltahir, Aya  ( St Georges Hospital , London , United Kingdom )
  • Peterzan, Mark  ( St Georges Hospital , London , United Kingdom )
  • Knott, Kristopher  ( St Georges Hospital , London , United Kingdom )
  • Ray, Robin  ( St Georges Hospital , London , United Kingdom )
  • Shanmugam, Nesan  ( St Georges Hospital , London , United Kingdom )
  • Anderson, Lisa  ( St Georges Hospital , London , United Kingdom )
  • Ghazal, Heba  ( Kingston University , Kingston , United Kingdom )
  • Author Disclosures:
    Mohamed Alalawi: DO NOT have relevant financial relationships | Fadi Jouhra: No Answer | Elizabeth Macken: DO NOT have relevant financial relationships | Taheba Begum: DO NOT have relevant financial relationships | Aya Eltahir: No Answer | Mark Peterzan: DO NOT have relevant financial relationships | Kristopher Knott: No Answer | Robin Ray: DO have relevant financial relationships ; Advisor:Pharmacosmos :Active (exists now) | Nesan Shanmugam: No Answer | Lisa Anderson: DO have relevant financial relationships ; Speaker:Alnylam:Past (completed) ; Other (please indicate in the box next to the company name):Astrazeneca, writing support for OverTTure and RevolutionHF studies:Active (exists now) ; Other (please indicate in the box next to the company name):Pfizer, research fellowship for a junior fellow:Past (completed) ; Advisor:Pharmacosmos:Past (completed) ; Advisor:Alnylam:Past (completed) ; Speaker:Vifor:Past (completed) | Heba Ghazal: DO NOT have relevant financial relationships
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

Patient Care Models in Heart Failure

Monday, 11/18/2024 , 09:30AM - 10:55AM

Moderated Digital Poster Session

More abstracts on this topic:
More abstracts from these authors:
Management of Iron Deficiency in Heart Population Treated in Heart Failure Unit and the Outlier Setting, A Comparison Study.

Kakhi Sorayya, Anderson Lisa, Ghazal Heba, Jouhra Fadi, Baig Muminah, Ali Abdullah Muminah, Alalawi Mohammed, Eltahir Aya, Bijman Laura, Peterzan Mark, Ray Robin, Shanmugam Nesan

You have to be authorized to contact abstract author. Please, Login
Not Available